Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy
Evolution and variation of tumor morphology during treatment may reflect or correlate with outcomes and contribute toward adapted response criteria.
Authors
- Chiara Vasco (ORCID: https://orcid.org/0000-0002-3788-778X)
- Laetitia Saccenti (ORCID: https://orcid.org/0000-0002-9765-0039)
- Bradford J. Wood (ORCID: https://orcid.org/0000-0002-4297-0051)
- Michael Kassin
- Donna Mabry
- Lindsey Hazen (ORCID: https://orcid.org/0000-0003-4013-8226)
- Cecilia Monge (ORCID: https://orcid.org/0000-0002-5558-2744)
- Sheng Xu (ORCID: https://orcid.org/0000-0002-1595-5382)
- Andrew S. Mikhail (ORCID: https://orcid.org/0000-0001-9206-5765)
- Tim F. Greten (ORCID: https://orcid.org/0000-0002-0806-2535)
- Austin G. Duffy (ORCID: https://orcid.org/0000-0001-9277-0157)
- Tabea Borde (ORCID: https://orcid.org/0000-0003-3019-5470)
- Nicole Varble (ORCID: https://orcid.org/0000-0003-2273-7962)
- Changqing Xie (ORCID: https://orcid.org/0000-0002-8489-4309)
- Elliot Levy
- Ifechi Ukeh
Institutions
- National Institutes of Health (US)
- Inserm (FR)
- Philips (United States) (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- La radiologia medica
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1007/s11547-024-01937-1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Société Française de Radiologie
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering
- NIH Clinical Center